BioArctic AB (publ) Total Liabilities

Latest as of June 2026: Skr802.78 Million SEK ≈ $86.39 Million USD

BioArctic AB (publ) total liabilities. Based on the latest financial reports, BioArctic AB (publ) (BIOA-B) has total liabilities worth Skr802.78 Million SEK (≈ $86.39 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BIOA-B cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of BioArctic AB (publ) (2015–2025)

Total liabilities of BioArctic AB (publ) from 2015 to 2025. This chart illustrates how BioArctic AB (publ)'s total liabilities have evolved over time, based on quarterly financial data.

BioArctic AB (publ) Competitors by Total Liabilities

The table below lists competitors of BioArctic AB (publ) ranked by their total liabilities.

Company Country Total Liabilities
Hugo Boss AG
XETRA:BOSS
Germany €2.11 Billion
Quectel Wireless Solutions Co Ltd
SHG:603236
China CN¥10.15 Billion
Robotis Co.Ltd
KQ:108490
Korea ₩10.97 Billion
KWS SAAT SE & Co. KGaA
F:KWS
Germany €1.12 Billion
Shanxi Securities Co Ltd
SHE:002500
China CN¥71.93 Billion
Attica Bank S.A.
AT:TATT
Greece €6.29 Billion
Bank of Xi'An Co Ltd
SHG:600928
China CN¥506.04 Billion
Hugo Boss AG
F:BOSA
Germany €1.90 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down BioArctic AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BioArctic AB (publ) assets under control.

Liquidity & Leverage Metrics

BioArctic AB (publ) Total Liabilities Ratios Explained

BioArctic AB (publ) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 3.99 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.40 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.28 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how BioArctic AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for BioArctic AB (publ) (2015–2025)

The table below shows the annual total liabilities of BioArctic AB (publ) from 2015 to 2025.

Year Total Liabilities Change
2025-12-31 Skr608.14 Million
≈ $65.45 Million
+180.59%
2024-12-31 Skr216.74 Million
≈ $23.32 Million
+55.37%
2023-12-31 Skr139.50 Million
≈ $15.01 Million
+93.58%
2022-12-31 Skr72.06 Million
≈ $7.76 Million
-33.92%
2021-12-31 Skr109.05 Million
≈ $11.74 Million
-23.75%
2020-12-31 Skr143.01 Million
≈ $15.39 Million
-31.52%
2019-12-31 Skr208.84 Million
≈ $22.47 Million
-44.36%
2018-12-31 Skr375.31 Million
≈ $40.39 Million
-25.59%
2017-12-31 Skr504.35 Million
≈ $54.28 Million
-22.07%
2016-12-31 Skr647.22 Million
≈ $69.65 Million
+2735.43%
2015-12-31 Skr22.83 Million
≈ $2.46 Million
--

About BioArctic AB (publ)

ST:BIOA-B Sweden Biotechnology
Market Cap
$2.54 Billion
Skr23.58 Billion SEK
Market Cap Rank
#5197 Global
#71 in Sweden
Share Price
Skr317.20
Change (1 day)
-0.69%
52-Week Range
Skr263.60 - Skr364.40
All Time High
Skr377.80
About

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for in… Read more